|
Commitments and Contingencies (Details Textual 1) (USD $)
|
12 Months Ended | 163 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2013
|
Aug. 31, 2012
Rental Agreement [Member]
|
Dec. 31, 2013
Rental Agreement [Member]
|
Jan. 27, 2014
Subsequent Event [Member]
Manufacturing Agreement [Member]
|
Dec. 31, 2013
Abbott Biotherapeutics Corp [Member]
Product Development and Patent License Agreement [Member]
|
Dec. 31, 2013
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
|
Dec. 31, 2013
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
Product Development and Patent License Agreement [Member]
|
Dec. 31, 2013
Abbott Biotherapeutics Corp [Member]
Phase 1 Clinical Trial of a licensed product [Member]
|
Dec. 31, 2012
MSKCC [Member]
Clinical Trial Agreement [Member]
|
Dec. 31, 2013
Oak Ridge National Laboratory [Member]
|
Dec. 31, 2013
Oak Ridge National Laboratory [Member]
2013 [Member]
|
Dec. 31, 2013
Oak Ridge National Laboratory [Member]
2014 [Member]
|
May 16, 2013
Aptiv Solutions [Member]
|
Oct. 22, 2012
Aptiv Solutions [Member]
|
Aug. 06, 2012
Aptiv Solutions [Member]
|
Dec. 31, 2007
Aptiv Solutions [Member]
|
Dec. 31, 2013
Aptiv Solutions [Member]
|
Dec. 31, 2012
Aptiv Solutions [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Dec. 31, 2013
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Dec. 31, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Dec. 31, 2013
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
|
Jul. 19, 2012
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
Maximum [Member]
license and sponsored research agreement [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
Minimum [Member]
license and sponsored research agreement [Member]
|
Aug. 28, 2012
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
patients
|
Jul. 31, 2013
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
|
Sep. 26, 2012
Johns Hopkins University [Member]
Clinical Trial Agreement [Member]
|
Nov. 21, 2012
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
|
Dec. 31, 2013
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
|
Mar. 31, 2013
Former Chief Executive Officer [Member]
Separation and Settlement Agreement [Member]
|
Dec. 31, 2013
Former Chief Executive Officer [Member]
Separation and Settlement Agreement [Member]
|
Feb. 28, 2013
Former Chief Executive Officer [Member]
Separation and Settlement Agreement [Member]
|
|
| Commitments and Contingencies (Textual) | |||||||||||||||||||||||||||||||||||
| Net sales in milestones payment | $ 10,000,000 | $ 1,000,000 | |||||||||||||||||||||||||||||||||
| License fee payment | 3,000,000 | ||||||||||||||||||||||||||||||||||
| Milestones payments | 7,750,000 | 1,500,000 | 750,000 | ||||||||||||||||||||||||||||||||
| Description of royalty payment | Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. | Royalty payments of 2% of net sales will be due to FHCRC. | |||||||||||||||||||||||||||||||||
| Royalty of Net Sales Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
| First commercial sale period | 12 years 6 months | ||||||||||||||||||||||||||||||||||
| Purchase of radioactive material used for research and development | 233,100 | 300,000 | 400,000 | ||||||||||||||||||||||||||||||||
| Project estimated cost for clinical trials of drug Ac-225-HuM195 | 2,813,960 | 1,000,000 | 2,200,000 | ||||||||||||||||||||||||||||||||
| Down payment of project estimated cost percentage | 12.50% | ||||||||||||||||||||||||||||||||||
| Down payment for project | 1,900,000 | 239,000 | 239,000 | ||||||||||||||||||||||||||||||||
| Clinical trial cost for approval of food and drug administration | 23,500,000 | 13,200,000 | |||||||||||||||||||||||||||||||||
| Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years ) | 150,000 | ||||||||||||||||||||||||||||||||||
| Fund for Fred Hutchinson Cancer Research Center lab ( thereafter ) | 250,000 | ||||||||||||||||||||||||||||||||||
| Number of Patients | 24 | ||||||||||||||||||||||||||||||||||
| Amount paid to each patient after Completing clinical trial | 31,366 | 500,000 | 34,383 | 38,501 | 31,771 | ||||||||||||||||||||||||||||||
| Start-up fee for clinical trial | 79,623 | 19,749 | 33,946 | 22,847 | 16,000 | ||||||||||||||||||||||||||||||
| Start-up due cost paid date | Dec. 31, 2013 | ||||||||||||||||||||||||||||||||||
| Agreement consideration | The Company paid the former CEO $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid the former CEO a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012. | ||||||||||||||||||||||||||||||||||
| Performance bonus payable under agreement for service | 60,000 | ||||||||||||||||||||||||||||||||||
| Non - refundable institutional fee | 562,790 | 14,500 | |||||||||||||||||||||||||||||||||
| Annual pharmacy fee | 2,025 | ||||||||||||||||||||||||||||||||||
| Amendment processing fee | 500 | ||||||||||||||||||||||||||||||||||
| Notice period for termination of agreement | This agreement terminates on July 6, 2014. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination. | ||||||||||||||||||||||||||||||||||
| Rent agreement termination date | Mar. 31, 2014 | ||||||||||||||||||||||||||||||||||
| Rental agreement renewal description | The agreement automatically renews on a month-to-month basis and requires a two month notice of termination. | ||||||||||||||||||||||||||||||||||
| Payment of aggregate amount in installments | 125,000 | ||||||||||||||||||||||||||||||||||
| Outstanding payment of final installment for services by company | 125,000 | ||||||||||||||||||||||||||||||||||
| Payment of performance bonus for services by company | 60,000 | ||||||||||||||||||||||||||||||||||
| Accrued expenses | 16,000 | ||||||||||||||||||||||||||||||||||
| Accrued fees paid | 16,000 | ||||||||||||||||||||||||||||||||||
| Research recorded fees | $ 2,666,859 | $ 3,440,485 | $ 29,087,378 | $ 75,000 | $ 150,000 | ||||||||||||||||||||||||||||||